Research Analysts’ Recent Ratings Updates for AveXis (AVXS)

AveXis (NASDAQ: AVXS) recently received a number of ratings updates from brokerages and research firms:

  • 1/18/2018 – AveXis had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $150.00 price target on the stock.
  • 1/17/2018 – AveXis is now covered by analysts at Credit Suisse Group AG. They set an “outperform” rating and a $134.00 price target on the stock.
  • 1/9/2018 – AveXis had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $92.00 price target on the stock.
  • 1/9/2018 – AveXis was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company’s product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. “
  • 1/8/2018 – AveXis had its “buy” rating reaffirmed by analysts at BMO Capital Markets.
  • 1/5/2018 – AveXis was given a new $110.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.
  • 1/5/2018 – AveXis had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $135.00 price target on the stock. They wrote, “We would encourage buying on any AVXS weakness today, on the potential that the market may have understandably misunderstood what could be an atypical but stepped up process in terms of filing timelines for AVXS-101 in SMA type 1. Our take: Our base case (see our 15 June 2017 note) of a filing after pivotal STR1VE (NCT03306277) phase III data seems to have been improved upon. There are reasons to believe AveXis could file AVXS-101 by 3Q18, with a blue skies” scenario involving AVXS-101 approval by end-2018 or early-2019. We note AveXis’ appropriately non-promotional commentary when executing its duties in communicating status of important regulatory matters to the market.””
  • 1/5/2018 – AveXis was given a new $120.00 price target on by analysts at Morgan Stanley. They now have a “buy” rating on the stock.
  • 1/5/2018 – AveXis was given a new $122.00 price target on by analysts at UBS Group AG. They now have a “buy” rating on the stock.
  • 1/5/2018 – AveXis was given a new $132.00 price target on by analysts at Citigroup Inc. They now have a “buy” rating on the stock.
  • 12/21/2017 – AveXis was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 12/20/2017 – AveXis was given a new $110.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.
  • 12/14/2017 – AveXis was given a new $110.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.
  • 12/14/2017 – AveXis was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 12/1/2017 – AveXis was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.

AveXis Inc (NASDAQ:AVXS) traded up $5.10 during midday trading on Monday, reaching $118.81. The company had a trading volume of 354,362 shares, compared to its average volume of 762,196. The stock has a market capitalization of $4,081.50, a P/E ratio of -21.29 and a beta of 2.46. AveXis Inc has a 12 month low of $52.18 and a 12 month high of $119.00.

AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the firm posted ($0.87) earnings per share. research analysts anticipate that AveXis Inc will post -6.23 EPS for the current year.

In related news, VP Andrew F. Knudten sold 2,000 shares of AveXis stock in a transaction on Monday, December 4th. The stock was sold at an average price of $94.48, for a total transaction of $188,960.00. Following the transaction, the vice president now directly owns 7,000 shares in the company, valued at $661,360. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $109.75, for a total value of $1,646,250.00. Following the transaction, the insider now owns 1,808,386 shares in the company, valued at $198,470,363.50. The disclosure for this sale can be found here. Insiders have sold 57,340 shares of company stock worth $5,851,445 over the last quarter. 18.60% of the stock is owned by company insiders.

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply